About Greyledge Technologies
Greyledge Technologies was established by Dr. David C. Karli to meet emerging physician and patient demands to facilitate and utilize mechanisms of natural healing to augment and/or support treatment of disease. Dr. Karli also recognized the deficiency in product quality in the growing field and that Physicians didn’t know exactly what they were putting into their patients. In order to meet these first initiative, Greyledge has developed novel, manual laboratory-based methods to process autologous whole blood and bone marrow tissues to produce biologic preparations that are quality and quantity controlled to create a better product and higher level of research and development to advance the field of cellular therapies.
Each of our biologic preparations is carefully analyzed prior to the point at which a physician returns it to the patient. This way, we ensure quality, safety and effectiveness and to meet physician-specified compositions. Greyledge’s approach is flexible, allowing physicians to optimize their practice of medicine through maintaining the highest standards in preparing, analyzing, applying and learning from autologous PRP and BMC preparations.
If you’re a patient looking for the optimal way to meet your needs, or if you’re a physician looking to integrate Regenerative Medicine seamlessly into your practice, now is the time to reach out to Greyledge. If you’re ready, we’re ready.
The Greyledge Mission
Our mission is to leverage scientific advancements in creating and innovating quality controlled autologous biologic preparations, which enable physicians to optimize the practice of Regenerative Medicine.
Greyledge Technologies has created a technology platform that allows physicians the opportunity to integrate autologous PRP and BMC biologic preparations into their practice using a meticulously controlled cell processing facility, coupled with fully documented and validated sample analysis with every product produced.
Greyledge History Timeline
2003
Dr. Karli Joined The Steadman Clinic
2010
Greyledge Technologies Founded
2012
Second Lab Location Started
2013
Website Launched
2014
Published With Mishra A, Et Al. (2014) “Efficacy”
2015
US Patent #9,164,079 Issued
2016
Decision To Launch Nationwide Scale-Up Of Greyledge Technologies
2019
Greyledge expands into multiple States
2020
Greyledge restructures and Incorporates
2021
Gryeledge completes a seed capital raise of $2.5 Million
2021
Greyledge completes electronic data management system
The Greyledge Team
Executive Team
David C. Karli, MD MBA
Founder, Chief Executive Officer, board of directors
Greyledge operations are currently being led by company Founder and CEO – David Karli. He is responsible for all aspects of company development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to regenerative medicine.
After attending medical school at the University of Maryland, Dr. Karli completed his residency in Physical Medicine and Rehabilitation at Harvard Medical School. Subsequently, he joined the faculty at Harvard, serving as an Attending Physician with the Department of PM&R at Spaulding Rehabilitation Hospital, as well as working in the Department of Orthopedic Surgery at Mass General Hospital.
After joining the Steadman Clinic in 2003, Dr. Karli began to adopt the use of autologous-based therapies that were emerging in the field of regenerative medicine. He has continued to lead the effort required to refine the practice of regenerative medicine, and has published pivotal clinical results and lectured extensively. His practice has grown substantially and includes treating elite-level and professional athletes. As a result, Dr. Karli has been featured in high-level media publications such as the Wall Street Journal, New York Times, ESPN Magazine and Denver Magazine.
Dr. Karli recognized early on that understanding the composition of regenerative biologic preparations used in treating his patients would be critical to refining his practice of medicine. He also realized that a “one size fits all” approach to creating the therapeutic preparations wouldn’t meet the need for an evidence-based, precision medicine approach. As a result, he founded Greyledge. In support of his concept for regenerative medicine, he completed the COLA Laboratory Director training course, and obtained his MBA (Daniels College of Business, University of Denver).
Greyledge has achieved sustained profitability and is ready for scalable expansion. Dr. Karli is positioning the company to maintain its unique technology platform offering by tracking regulatory activity, advancing biologic sample analytics and quality measures, and creating protocols that allow for customization of patient biologic preparations.
Zoe Karli
President, board of directors
Zoe Karli, our President, and a Director, officially joined the Greyledge executive team in 2019. She graduated from the University of Virginia via a Navy ROTC scholarship in 2005, served active military duty, and then transitioned into the world of business, working with both seasoned and start-up companies. She is a seasoned medical, biotechnical, and direct sales professional, with expertise in sales, e-commerce, distributorship, and operations. She has held territory leadership roles in pharmaceutical sales with Novartis, 2006-2009, medical device sales with Depuy Spine, and in conjunction co-developed a successful private distributorship managing independent contractors for multiple product lines within medical device, pharmaceuticals, cosmetic and dental specialties, 2009-2017. She then began working behind the scenes with Greyledge Technologies to officially assume a Directorship role in 2019.
Jim Johnston
Chief of Corporate Development, BOARD OF directors
Jim Johnston serves as Chief of Business Development for Greyledge, reporting to the CEO with responsibility for the company’s overarching strategy, including long-term planning, global business and corporate development, and strategic investments, acquisitions and divestitures. Mr. Johnston has spent the past 21 years advising and investing in companies across a variety of industries and sizes. He has significant experience in financing, mergers and acquisitions, strategic execution and board level decision making. Jim was an investment banker at Goldman Sachs from 2000-2008 in Mergers and Acquisitions and Financial Sponsor Coverage. He left as a Vice President and joined Nexphase Capital Partners (FKA Moelis Capital Partners) in 2008 where he ultimately ran the Industrials Group as a Partner. In 2018, Mr. Johnston left Nexphase and founded Emerald Lake Advisors in order to focus his energy on investing and advising small entrepreneurial companies.
Mr. Johnston serves on the board of directors of the Red Fox Community School and as a board observer of Jame Rollform Products. He received a BS in Commerce with Distinction from the University of Virginia in 1991 and was commissioned as a Naval Officer through the ROTC program. After graduating Nuclear Power School and Prototype he served as a submarine officer and is a qualified Naval Nuclear Engineer. After his separation from the Navy, he received his MBA from Harvard Business School in 2000.
Mr. Johnston is married with three sons and volunteers as a basketball and baseball coach in his local community.
Richard C. Bedford
Director of Strategy and Innovation
Dick Bedford is a strategic thinker known for his ability to evaluate, deconstruct and solve complex problems. He worked for NATO helping senior leaders develop strategy and generate solutions. A former naval officer, he spent 25 years in the U.S. Navy commanding both at sea and ashore, retiring as a Captain. He served in a multitude of command and operational billets both in the US and Europe, and while flying, logged over 3800 hours in the F-14, to include 75 combat hours.
Mr. Bedford graduated from Tulane University in 1978 receiving a Bachelor of Science in Engineering; graduated from Harvard University in 1991, receiving a Master in Public Administration degree from the John F. Kennedy School of Government; and, from Georgetown University in 1998 where as a Moreau fellow he received a Master in National Security Studies from the Walsh School of Foreign Service. He is also a seminar graduate of the National Defense University School for Information and Resources Management in Washington DC and a 2000 graduate of the Harvard University School for Senior Executive Fellows in Cambridge, MA.
Connor Callen
Director of Data Systems and Analytics
Connor Callen serves as the Director of Data Systems and Analytics for Greyledge. Connor designs and orchestrates the data ecosystem, software, and analytics that power Greyledge’s vision. Connor graduated from the University of Colorado: Boulder in 2018 with a degree in Biochemical Engineering. He previously worked at IBM in various engineering and project management roles before returning to the medical field as a territory manager in the medical device field.
In addition, Mr. Callen also serves as a consultant to the Karli Center where he works with the Karli executive team to integrate the Greyledge data model into the Center’s EMR platform.
Scientific Research and Development Team
Denis Polancec, PhD
Senior Scientist
Denis Polancec, PhD joined Greyledge technologies in August 2022 as a senior scientist. He had worked for 15 years as a head of the flow cytometry and cell sorting laboratory in a research institute within a pharmaceutical company. After that he started to work in a children's hospital as a Head of Translational Medicine Department. On both positions his responsibilities were establishing and running of flow cytometry laboratory and development of various polychromatic flow cytometry assays. Additionaly, he was involved in teaching graduate or PhD students in basic and advanced flow cytometry as well as helping various laboratories regarding sample preparation and management, acquisition on flow cytometer and subsequent offline analysis of listmode data files.
Denis will be working on different regenerative medicine projects including immunophenotyping of a stromal vascular fraction from micro- fragmented lipoaspirate, flow cytometry analysis of adipose-derived mesenchymal stem cells and stem cells from bone marrow aspirates and platelet-rich plasma preparations.
Lucija Zenic, PhD
senior scientist
Lucija Zenic, PhD has joined the Greyledge Technologies team as a senior scientist to reinforce translational research and contribute to the company's vision of regenerative medicine.
As a molecular biologist (University of Zagreb, Croatia) holding a PhD in immunology (University of Gothenburg, Sweden), she had worked for years as a public healthcare scientist in the field of translational medicine, successfully implementing new diagnostic methods into clinical practice while running molecular diagnostics and genetic lab.
Having worked and published in the field of stem cell-based regenerative medicine, she holds experience in immunophenotypic characterization of regenerative cells with therapeutic application and understands the crucial importance of fully profiling such therapeutics in order to complete mechanistic and functional explanations.
Ultimatively, she seeks to couple new techniques and protocols for advancing and customizing patient biologic preparations in the context of personalized regenerative and genomic medicine.
Board of Advisors
David C. Karli, MD MBA
Founder, Chief Executive Officer, board of directors
Greyledge operations are currently being led by company Founder and CEO – David Karli. He is responsible for all aspects of company development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to regenerative medicine.
After attending medical school at the University of Maryland, Dr. Karli completed his residency in Physical Medicine and Rehabilitation at Harvard Medical School. Subsequently, he joined the faculty at Harvard, serving as an Attending Physician with the Department of PM&R at Spaulding Rehabilitation Hospital, as well as working in the Department of Orthopedic Surgery at Mass General Hospital.
After joining the Steadman Clinic in 2003, Dr. Karli began to adopt the use of autologous-based therapies that were emerging in the field of regenerative medicine. He has continued to lead the effort required to refine the practice of regenerative medicine, and has published pivotal clinical results and lectured extensively. His practice has grown substantially and includes treating elite-level and professional athletes. As a result, Dr. Karli has been featured in high-level media publications such as the Wall Street Journal, New York Times, ESPN Magazine and Denver Magazine.
Dr. Karli recognized early on that understanding the composition of regenerative biologic preparations used in treating his patients would be critical to refining his practice of medicine. He also realized that a “one size fits all” approach to creating the therapeutic preparations wouldn’t meet the need for an evidence-based, precision medicine approach. As a result, he founded Greyledge. In support of his concept for regenerative medicine, he completed the COLA Laboratory Director training course, and obtained his MBA (Daniels College of Business, University of Denver).
Greyledge has achieved sustained profitability and is ready for scalable expansion. Dr. Karli is positioning the company to maintain its unique technology platform offering by tracking regulatory activity, advancing biologic sample analytics and quality measures, and creating protocols that allow for customization of patient biologic preparations.
Zoe Karli
President, board of directors
Zoe Karli, our President, and a Director, officially joined the Greyledge executive team in 2019. She graduated from the University of Virginia via a Navy ROTC scholarship in 2005, served active military duty, and then transitioned into the world of business, working with both seasoned and start-up companies. She is a seasoned medical, biotechnical, and direct sales professional, with expertise in sales, e-commerce, distributorship, and operations. She has held territory leadership roles in pharmaceutical sales with Novartis, 2006-2009, medical device sales with Depuy Spine, and in conjunction co-developed a successful private distributorship managing independent contractors for multiple product lines within medical device, pharmaceuticals, cosmetic and dental specialties, 2009-2017. She then began working behind the scenes with Greyledge Technologies to officially assume a Directorship role in 2019.
Jim Johnston
Chief of Corporate Development, BOARD OF directors
Jim Johnston serves as Chief of Business Development for Greyledge, reporting to the CEO with responsibility for the company’s overarching strategy, including long-term planning, global business and corporate development, and strategic investments, acquisitions and divestitures. Mr. Johnston has spent the past 21 years advising and investing in companies across a variety of industries and sizes. He has significant experience in financing, mergers and acquisitions, strategic execution and board level decision making. Jim was an investment banker at Goldman Sachs from 2000-2008 in Mergers and Acquisitions and Financial Sponsor Coverage. He left as a Vice President and joined Nexphase Capital Partners (FKA Moelis Capital Partners) in 2008 where he ultimately ran the Industrials Group as a Partner. In 2018, Mr. Johnston left Nexphase and founded Emerald Lake Advisors in order to focus his energy on investing and advising small entrepreneurial companies.
Mr. Johnston serves on the board of directors of the Red Fox Community School and as a board observer of Jame Rollform Products. He received a BS in Commerce with Distinction from the University of Virginia in 1991 and was commissioned as a Naval Officer through the ROTC program. After graduating Nuclear Power School and Prototype he served as a submarine officer and is a qualified Naval Nuclear Engineer. After his separation from the Navy, he received his MBA from Harvard Business School in 2000.
Mr. Johnston is married with three sons and volunteers as a basketball and baseball coach in his local community.
Michael Coleman
research scientist and executive
Dr. Michael Coleman has more than 28 years of experience as a research scientist and executive in the biotechnology, medical device, and pharmaceutical industries. He received his baccalaureate and doctoral degrees at Texas A&M University and The Pennsylvania State University and did postdoctoral research at Baylor College of Medicine. During his career, Dr. Coleman has led the development of gene therapies, medical devices, and regenerative medicine products in the USA and EU. He has been continuously involved in the development and commercialization of regenerative medicine products since 2006. He is currently CEO of Metaclipse Therapeutics, an Atlanta-based biotech company developing immunotherapies for cancer and vaccines for infectious diseases.
Adi Karisik
Global Technology Principal – OT Cybersecurity
Division Lead – Divergent Solutions – OT Cybersecurity
Adi Karisik is a global leader with over 20 years of highly specialized professional experience, one that covers information technology, enterprise IT cyber security, Operational Technology, management consulting, and intelligence consulting as well as providing specialized services in Defense and Intelligence domains. He managed several classified and open programs/portfolios in both USA and Europe. During his 14-year tenure with Blue Canopy Group, Mr. Karisik served as a partner and one of the key leaders in National Security.
Mr. Karisik’s skillset is very colorful, totally not unlike his work experience, and involves behavioral profiling, cultural analysis, political-military advising, combat operations, intelligence training, predictive threat analysis, etc. – just to name a few. He worked in over 80 countries and speaks multiple languages.
His work experience covers a variety of organizations in the intelligence arena and within the Department of Defense, Mr. Karisik is well known within Army, United States Marine Corps, and specialized community. He teaches at Naval Post Graduate School in Monterey and has authored several types of training in areas of cross-cultural negotiations, predictive behavior analysis, human terrain reading, and survivability.
Since 2012 Adi has been involved in big data analytics and has partnered with several US and European companies to provide a product capable of combining big data and machine learning with multiple external data sources, in order to facilitate assistance in the area of complex decision-making modeling.
Since 2017 Mr. Karisik has been involved in setting up a focused Operational Technology Services Practice within Jacobs. Currently, the practice covers several hundreds of clients globally. Adi is a passionate pilot, a former nationally ranked NCAA Division 1 tennis coach, and active in Civil Air Patrol where he volunteers his time to train cadets and fly search and rescue missions.
At Jacobs, Mr. Karisik served as Deputy BU Leader for Cybersecurity and as a BU Leader for Commercial and International Cybersecurity within National Security Solutions/CMS. In February 2019 he joined our P&PS line of business in NYC PU-based Operational Technology Services Group and started managing it. The group grew over 12 times, and Operational Technology has been recognized and established as a separate technology under Jacobs Digital Market. In 2022 Adi joined the Divergent Solutions Line of Business and since then he leads Jacobs OT Cybersecurity division from there.
Adi lives in the Washington DC area with his wife, a daughter, and a son.
